Company intelligence / Profile preview

Manas AI

New York City, New York, USA

Ownership: Private
Development stage: Preclinical

Overview

Manas AI has recently launched with $24.6 million in seed funding to develop an integrated platform for rapid identification of novel therapeutics using proprietary artificial intelligence. The company’s initial programs are preclinical, targeting aggressive cancers with plans to expand into autoimmune and rare diseases. No clinical results have been reported yet as the company is in its early stages

Therapeutic areas: OncologyRare DiseasesImmunology
Modalities: Small molecules
Industry: Biotech

Partnerships

Microsoft – partnership leveraging Microsoft Azure cloud computing infrastructure and domain expertise in artificial intelligence to accelerate drug discovery efforts

Beyond the preview

Go deeper on Manas AI.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Manas AI.

Explore the full profile